Anti-human ige monoclonal antibodies
CA 2086131 C · Owner: Daiichi Pharmaceutical Co. Ltd. · Inventors: Washida, Naohiro; Yoshida, Toshiko
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Monoclonal antibodies specifically bind to human immunoglobulin E (IgE) and are characterized by the following properties. Molecular weight of approximately 150,000 determined by SDS-polyacrylamide gel electrophoresis (non-reduced state). 2. Bind to human IgE-producing B cells. 3. Recognize IgE bound to human or canine cell having Fc.epsilon. receptor. 4. Antibodies having one of sequences No. 1 to 4 in the sequence list of the Nterminal amino acid of the L-chain. The antibodies bind specifically to IgE and are useful for the treatment of allergy and other medicines.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 23, 1992 and granted May 13, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 23, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 23, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.